Cargando…

Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fcγ Receptor Inhibition and Activation in Endosomes

The inhibition of Fcγ receptors (FcγR) is an attractive strategy for treating diseases driven by IgG immune complexes (IC). Previously, we demonstrated that an engineered tri-valent arrangement of IgG1 Fc domains (SIF1) potently inhibited FcγR activation by IC, whereas a penta-valent Fc molecule (Pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Elizabeth M., Choudhury, Amit, Vuppula, Harika, Ortiz, Daniel F., Schaeck, John, Manning, Anthony M., Bosques, Carlos J., Hoppe, Adam D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928370/
https://www.ncbi.nlm.nih.gov/pubmed/33679705
http://dx.doi.org/10.3389/fimmu.2020.617767
_version_ 1783659841881899008
author Bailey, Elizabeth M.
Choudhury, Amit
Vuppula, Harika
Ortiz, Daniel F.
Schaeck, John
Manning, Anthony M.
Bosques, Carlos J.
Hoppe, Adam D.
author_facet Bailey, Elizabeth M.
Choudhury, Amit
Vuppula, Harika
Ortiz, Daniel F.
Schaeck, John
Manning, Anthony M.
Bosques, Carlos J.
Hoppe, Adam D.
author_sort Bailey, Elizabeth M.
collection PubMed
description The inhibition of Fcγ receptors (FcγR) is an attractive strategy for treating diseases driven by IgG immune complexes (IC). Previously, we demonstrated that an engineered tri-valent arrangement of IgG1 Fc domains (SIF1) potently inhibited FcγR activation by IC, whereas a penta-valent Fc molecule (PentX) activated FcγR, potentially mimicking ICs and leading to Syk phosphorylation. Thus, a precise balance exists between the number of engaged FcγRs for inhibition versus activation. Here, we demonstrate that Fc valency differentially controls FcγR activation and inhibition within distinct subcellular compartments. Large Fc multimer clusters consisting of 5-50 Fc domains predominately recruited Syk-mScarlet to patches on the plasma membrane, whereas PentX exclusively recruited Syk-mScarlet to endosomes in human monocytic cell line (THP-1 cells). In contrast, SIF1, similar to monomeric Fc, spent longer periods docked to FcγRs on the plasma membrane and did not accumulate and recruit Syk-mScarlet within large endosomes. Single particle tracking (SPT) of fluorescent engineered Fc molecules and Syk-mScarlet at the plasma membrane imaged by total internal reflection fluorescence microscopy (SPT-TIRF), revealed that Syk-mScarlet sampled the plasma membrane was not recruited to FcγR docked with any of the engineered Fc molecules at the plasma membrane. Furthermore, the motions of FcγRs docked with recombinant Fc (rFc), SIF1 or PentX, displayed similar motions with D ~ 0.15 μm(2)/s, indicating that SIF1 and PentX did not induce reorganization or microclustering of FcγRs beyond the ligating valency. Multicolor SPT-TIRF and brightness analysis of docked rFc, SIF1 and PentX also indicated that FcγRs were not pre-assembled into clusters. Taken together, activation on the plasma membrane requires assembly of more than 5 FcγRs. Unlike rFc or SIF1, PentX accumulated Syk-mScarlet on endosomes indicating that the threshold for FcγR activation on endosomes is lower than on the plasma membrane. We conclude that the inhibitory effects of SIF1 are mediated by stabilizing a ligated and inactive FcγR on the plasma membrane. Thus, FcγR inhibition can be achieved by low valency ligation with SIF1 that behaves similarly to FcγR docked with monomeric IgG.
format Online
Article
Text
id pubmed-7928370
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79283702021-03-04 Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fcγ Receptor Inhibition and Activation in Endosomes Bailey, Elizabeth M. Choudhury, Amit Vuppula, Harika Ortiz, Daniel F. Schaeck, John Manning, Anthony M. Bosques, Carlos J. Hoppe, Adam D. Front Immunol Immunology The inhibition of Fcγ receptors (FcγR) is an attractive strategy for treating diseases driven by IgG immune complexes (IC). Previously, we demonstrated that an engineered tri-valent arrangement of IgG1 Fc domains (SIF1) potently inhibited FcγR activation by IC, whereas a penta-valent Fc molecule (PentX) activated FcγR, potentially mimicking ICs and leading to Syk phosphorylation. Thus, a precise balance exists between the number of engaged FcγRs for inhibition versus activation. Here, we demonstrate that Fc valency differentially controls FcγR activation and inhibition within distinct subcellular compartments. Large Fc multimer clusters consisting of 5-50 Fc domains predominately recruited Syk-mScarlet to patches on the plasma membrane, whereas PentX exclusively recruited Syk-mScarlet to endosomes in human monocytic cell line (THP-1 cells). In contrast, SIF1, similar to monomeric Fc, spent longer periods docked to FcγRs on the plasma membrane and did not accumulate and recruit Syk-mScarlet within large endosomes. Single particle tracking (SPT) of fluorescent engineered Fc molecules and Syk-mScarlet at the plasma membrane imaged by total internal reflection fluorescence microscopy (SPT-TIRF), revealed that Syk-mScarlet sampled the plasma membrane was not recruited to FcγR docked with any of the engineered Fc molecules at the plasma membrane. Furthermore, the motions of FcγRs docked with recombinant Fc (rFc), SIF1 or PentX, displayed similar motions with D ~ 0.15 μm(2)/s, indicating that SIF1 and PentX did not induce reorganization or microclustering of FcγRs beyond the ligating valency. Multicolor SPT-TIRF and brightness analysis of docked rFc, SIF1 and PentX also indicated that FcγRs were not pre-assembled into clusters. Taken together, activation on the plasma membrane requires assembly of more than 5 FcγRs. Unlike rFc or SIF1, PentX accumulated Syk-mScarlet on endosomes indicating that the threshold for FcγR activation on endosomes is lower than on the plasma membrane. We conclude that the inhibitory effects of SIF1 are mediated by stabilizing a ligated and inactive FcγR on the plasma membrane. Thus, FcγR inhibition can be achieved by low valency ligation with SIF1 that behaves similarly to FcγR docked with monomeric IgG. Frontiers Media S.A. 2021-02-15 /pmc/articles/PMC7928370/ /pubmed/33679705 http://dx.doi.org/10.3389/fimmu.2020.617767 Text en Copyright © 2021 Bailey, Choudhury, Vuppula, Ortiz, Schaeck, Manning, Bosques and Hoppe http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Bailey, Elizabeth M.
Choudhury, Amit
Vuppula, Harika
Ortiz, Daniel F.
Schaeck, John
Manning, Anthony M.
Bosques, Carlos J.
Hoppe, Adam D.
Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fcγ Receptor Inhibition and Activation in Endosomes
title Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fcγ Receptor Inhibition and Activation in Endosomes
title_full Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fcγ Receptor Inhibition and Activation in Endosomes
title_fullStr Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fcγ Receptor Inhibition and Activation in Endosomes
title_full_unstemmed Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fcγ Receptor Inhibition and Activation in Endosomes
title_short Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fcγ Receptor Inhibition and Activation in Endosomes
title_sort engineered igg1-fc molecules define valency control of cell surface fcγ receptor inhibition and activation in endosomes
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928370/
https://www.ncbi.nlm.nih.gov/pubmed/33679705
http://dx.doi.org/10.3389/fimmu.2020.617767
work_keys_str_mv AT baileyelizabethm engineeredigg1fcmoleculesdefinevalencycontrolofcellsurfacefcgreceptorinhibitionandactivationinendosomes
AT choudhuryamit engineeredigg1fcmoleculesdefinevalencycontrolofcellsurfacefcgreceptorinhibitionandactivationinendosomes
AT vuppulaharika engineeredigg1fcmoleculesdefinevalencycontrolofcellsurfacefcgreceptorinhibitionandactivationinendosomes
AT ortizdanielf engineeredigg1fcmoleculesdefinevalencycontrolofcellsurfacefcgreceptorinhibitionandactivationinendosomes
AT schaeckjohn engineeredigg1fcmoleculesdefinevalencycontrolofcellsurfacefcgreceptorinhibitionandactivationinendosomes
AT manninganthonym engineeredigg1fcmoleculesdefinevalencycontrolofcellsurfacefcgreceptorinhibitionandactivationinendosomes
AT bosquescarlosj engineeredigg1fcmoleculesdefinevalencycontrolofcellsurfacefcgreceptorinhibitionandactivationinendosomes
AT hoppeadamd engineeredigg1fcmoleculesdefinevalencycontrolofcellsurfacefcgreceptorinhibitionandactivationinendosomes